Global pharmaceutical giant Novo Nordisk has significantly strengthened its position in the treatment landscape for Metabolic Dysfunction-associated Steatohepatitis (MASH) with... Read more
Novo Nordisk Secures Key MASH Therapy in $5.2 Billion Strategic Deal
06/12/2025
Published by vivi




